A real-world drug safety surveillance study of lenvatinib from the FAERS database.
[BACKGROUND] There is a need to determine lenvatinib-associated real-world adverse events (AEs) as its adverse effects may result in its discontinuation.
APA
Yang Y, Wang Y, et al. (2025). A real-world drug safety surveillance study of lenvatinib from the FAERS database.. Expert opinion on drug safety, 24(10), 1207-1219. https://doi.org/10.1080/14740338.2024.2393284
MLA
Yang Y, et al.. "A real-world drug safety surveillance study of lenvatinib from the FAERS database.." Expert opinion on drug safety, vol. 24, no. 10, 2025, pp. 1207-1219.
PMID
39145923
Abstract
[BACKGROUND] There is a need to determine lenvatinib-associated real-world adverse events (AEs) as its adverse effects may result in its discontinuation.
[RESEARCH DESIGN AND METHODS] Lenvatinib-associated AEs were analyzed and quantified and risk signals from the first quarter of 2015 to the fourth quarter of 2023 were detected through data mining. Potential targets for lenvatinib-associated cholecystitis, cholangitis, and hepatic encephalopathy were identified by data mining.
[RESULT] 68 Preferred Terms (PTs) with an important imbalance were kept. Unexpected AEs, such as immune-mediated hepatitis, portal vein thrombosis and adrenal insufficiency were associated with the use of lenvatinib use. Lenvatinib alone was more strongly associated with adrenal insufficiency than lenvatinib and pembrolizumab combination. Hepatic encephalopathy was more strongly correlated with drug use when Lenvatinib was administered to male patients with hepatocellular carcinoma. Most AEs occurred during the first month after treatment, with a median onset time of 41 days. FGFR4, PDGFRA, and KIT (Lenvatinib targets) are potentially linked to cholecystitis, cholangitis, and hepatic encephalopathy.
[CONCLUSIONS] We identified Lenvatinib-associated AEs and discovered new AEs that will be useful for clinical monitoring and risk assessment.
[RESEARCH DESIGN AND METHODS] Lenvatinib-associated AEs were analyzed and quantified and risk signals from the first quarter of 2015 to the fourth quarter of 2023 were detected through data mining. Potential targets for lenvatinib-associated cholecystitis, cholangitis, and hepatic encephalopathy were identified by data mining.
[RESULT] 68 Preferred Terms (PTs) with an important imbalance were kept. Unexpected AEs, such as immune-mediated hepatitis, portal vein thrombosis and adrenal insufficiency were associated with the use of lenvatinib use. Lenvatinib alone was more strongly associated with adrenal insufficiency than lenvatinib and pembrolizumab combination. Hepatic encephalopathy was more strongly correlated with drug use when Lenvatinib was administered to male patients with hepatocellular carcinoma. Most AEs occurred during the first month after treatment, with a median onset time of 41 days. FGFR4, PDGFRA, and KIT (Lenvatinib targets) are potentially linked to cholecystitis, cholangitis, and hepatic encephalopathy.
[CONCLUSIONS] We identified Lenvatinib-associated AEs and discovered new AEs that will be useful for clinical monitoring and risk assessment.
MeSH Terms
Humans; Quinolines; Phenylurea Compounds; Male; Antineoplastic Agents; Adverse Drug Reaction Reporting Systems; Databases, Factual; Female; Middle Aged; Data Mining; Aged; Adult; Sex Factors; Liver Neoplasms; Carcinoma, Hepatocellular; Protein Kinase Inhibitors; Time Factors
같은 제1저자의 인용 많은 논문 (5)
- Super-selective intra-arterial dissolution therapy for lingual artery occlusion resulting due to the use of hyaluronic acid for chin augmentation: The first reported case.
- NAT10 and ac4C modification in cancer immunity and metabolism: emerging mechanisms and therapeutic potential.
- Engineering polymeric RNA scaffolds as programmable combinatorial innate immune agonists.
- HDAC11 interacts with the NuRD (MTA3) complex to transcriptionally suppress TGFβ1 expression and inhibit hepatocellular carcinoma metastasis.
- Targeting palmitoylation: A novel frontier in cancer biology and immunotherapy.